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Abstract
The effect of hyperoxygenation with carbogen (95% O2 + 5% CO2) inhalation on RIF-1 tumor
pO2 and its consequence on growth inhibition with fractionated radiotherapy is reported. The
temporal changes in the tumor pO2 were assessed by in vivo Electron Paramagnetic Resonance
(EPR) oximetry in mice breathing 30% O2 or carbogen and the tumors were irradiated with 4 Gy/
day for 5 consecutive days; a protocol that emulates the clinical application of carbogen. The
RIF-1 tumors were hypoxic with a tissue pO2 of 5 – 9 mm Hg. Carbogen (CB) breathing
significantly increased tumor pO2, with a maximum increase at 22.9 – 31.2 min on days 1 – 5,
however, the magnitude of increase in pO2 declined on day 5. Radiotherapy during carbogen
inhalation (CB/RT) resulted in a significant tumor growth inhibition from day 3 to day 6 as
compared to 30%O2/RT and carbogen (CB/Sham RT) groups. The results provide unambiguous
quantitative information on the effect of carbogen inhalation on tumor pO2 over the course of 5
days. Tumor growth inhibition in the CB/RT group confirms that the tumor oxygenation with
carbogen was radiobiologically significant. Repeated tumor pO2 measurements by EPR oximetry
can provide temporal information that could be used to improve therapeutic outcomes by
scheduling doses at times of improved tumor oxygenation.
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INTRODUCTION
Tumor hypoxia leads to therapeutic resistance (1–3) and also promotes aggressive tumor
behavior and metastases (4, 5). Therefore, a significant therapeutic benefit can be achieved by
improving tumor oxygenation. Several methods have been developed to increase tumor
oxygenation such as by using gases with high oxygen content at normobaric or hyperbaric
pressures (6, 7), carbogen (95% O2 + 5% CO2) breathing, carbogen combined with
nicotinamide (8–10), administration of hypoxic-cell sensitizers (11, 12), and erythropoietin to
improve hemoglobin level (13, 14). Although these methods have led to mixed results, it is
generally agreed that radiotherapeutic outcome should improve, if an effective strategy is
established to reduce tumor hypoxia.
Carbogen (CB) inhalation seems to be the most effective method to enhance the radiation
response of experimental tumors (12, 15, 16). The clinical ARCON therapy (accelerated
radiotherapy with carbogen and nicotinamide) utilizing carbogen with nicotinamide has also
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led to promising results (9), however, the mechanism of hyperoxic hypercapnic gas such as
carbogen remains unclear (17). Appropriate oximetry techniques that can provide repeated
assessments of tumor pO2 are necessary to optimize hypoxia modifying methods and
efficaciously combine with radiotherapy.
In vivo Electron Paramagnetic Resonance (EPR) oximetry has the ability to provide repeated
measurements of tumor pO2 to test and optimize methods designed to increase tumor
oxygenation and demonstrate therapeutic optimization(18–22). We report the effect of
carbogen inhalation on the tissue pO2 of subcutaneous RIF-1 tumors. The maximum
increase in the tumor pO2 and the time to reach the maximum pO2 during carbogen
inhalation were determined by EPR oximetry. This crucial information was used to
investigate therapeutic outcome by irradiating the tumors with 4 Gy/day for 5 days at the
time of a maximum increase in the tumor pO2.
MATERIALS AND METHODS
1. Study design
The effect of carbogen (CB) inhalation on RIF-1 tumor pO2 was measured by EPR oximetry
for 5 consecutive days and the changes in the tumor pO2, maximum pO2 (pO2 max), and the
time to reach to maximum pO2 (T max) were assessed (CB alone group, N = 14). The tumor
pO2 was assessed prior to and during carbogen inhalation and the tumors were irradiated
with 4 Gy at T max and these experiments were repeated for 5 consecutive days (CB/RT
treatment group, N = 16). In group 30% O2/RT, the tumors were irradiated with 4 Gy in
mice breathing 30% oxygen (30% O2/RT treatment group, N = 9). In group CB/sham RT,
the tumors were treated with sham irradiation (0 Gy) in mice breathing carbogen (CB/sham
irradiation group, N = 6). The inspired gas of 30% O2 (balanced N2) provides blood pO2
values in the normal range and therefore this gas mixture is routinely used in our laboratory
(18, 19, 23–25).
General methods
Tumor models—The radiation-induced fibrosarcoma (RIF-1) cells were a gift from Dr. J.
B. Mitchell’s laboratory at the National Cancer Institute. This is a well established
subcutaneous tumor model used extensively in our lab (18, 24). The cells were cultured in
RPMI 1640 medium supplemented with 10% FBS, glutamine, and antibiotics. The
procedure for tumor inoculation has been reported previously (24). Briefly, 18 – 20g female
C3H/HEJ mice (4 – 5 weeks age, Charles River Lab, MA) were anesthetized by 1.5%
isoflurane with 30% O2, and a suspension of 2 × 105 cells in 60 – 80 μl was injected
subcutaneously into the left posterior flank. The tumors were allowed to grow for 12 – 14
days and oxygen sensitive lithium phthalocyanine (LiPc, oximetry probe) crystals were
implanted into the tumors as described below. The tumor volumes were estimated using the
formula: π/6 × length × width2 for six days.
Oximetry probe and EPR (Electron Paramagnetic Resonance) oximetry—LiPc
crystals were synthesized in our laboratory; its physicochemical properties and use for tissue
pO2 measurement have been described previously (26, 27). LiPc has a single sharp EPR line
whose width is highly sensitive to pO2. The EPR spectra reflect the average partial pressure
of oxygen on the surface of the crystals. The high density of unpaired spins combined with a
narrow intrinsic line width of LiPc allows the measurements of tissue pO2 using a few
crystals (30–50 μg) with a total diameter of ~ 200 μm. For LiPc implantations, the mice
were anesthetized (1.5% isoflurane, 30% O2), and two aggregates of LiPc crystals (30–50
μg each) were implanted into each tumor using 25 gauge needles and wire styluses. In order
to simultaneously assess pO2 at two locations in the tumor, we have used two LiPc
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aggregates with appropriate magnetic field gradients to resolve the EPR signals. The
magnitude of the gradient required to separate the spectra, while minimizing additional
broadening of the EPR lines, depends on the actual line width, size of the implants and the
distance between them. In these experiments, the distance between LiPc aggregates was 4
mm to minimize magnetic field gradient and its effect on the EPR line widths. The
procedure for multi-site EPR oximetry is described by Smirnov et al. (28) and this approach
has been used to study pO2 at multiple locations in the tumors (18, 19, 23–25). The tissue pO2
measured from the two LiPc implants in each tumor were pooled to determine average
tumor pO2 on each day (18, 19, 24). The EPR line widths were converted to pO2 using a
calibration determined for the LiPc crystals used in this study. The pO2 max and T max
from each implant were determined, and then averaged to obtain individual mean for each
group.
Procedure for carbogen inhalation and irradiation—The mice were anesthetized
(1.5 % isoflurane, 30% O2) 24 hr after LiPc implantation and the baseline pO2 (day 1) was
measured for 20 min in CB group. The breathing gas was then switched to carbogen and
oximetry measurements were continued for 60 min to determine the effect of carbogen
inhalation on the tumor pO2. The pO2 max and T max were determined and used to design
radiotherapy (RT) groups. In the CB/RT group, first a baseline pO2 was measured in mice
breathing 30% O2 and then the mice were allowed to breathe carbogen. The tumor pO2 was
measured for 15 min and then the mice were moved to the irradiation bed of a Varian Linear
Accelerator (Clinac 2100C, 6 Mev, 6 cm × 6 cm applicator). In this group, the mice
continued to breathe carbogen during irradiation with 4Gy. The beam was focused on the
tumor and appropriate lead shields were used to limit irradiation of the normal tissue. The
approximate time between the end of the EPR measurements and beginning of the
irradiation was 6 – 8 min. The total time to irradiate each tumor with 4Gy took
approximately 1.8 min on each day. In 30% O2/RT group, the tumor pO2 measurements
were continued for 15 min in mice breathing 30% O2 after baseline measurements and the
tumors were irradiated using the procedure described for the CB/RT group. In CB/sham RT
group, after baseline and 15 min of carbogen breathing, the tumors received sham irradiation
(0 Gy), and then the mice were moved back to the EPR spectrometer for pO2 measurements
for at least 10 min. These experiments were repeated for 5 consecutive days.
The tumor pO2 measured on day 1 prior to any treatment is termed as baseline pO2, while
the initial pO2 measured on days 2 – 5 in the first 20 min is termed as pre-treatment pO2.
Similar terms are used for tumor volume measurement in these experiments.
Physiological control and histological analysis—During tumor pO2 measurements,
the body temperature of the animals was monitored using a rectal probe and maintained at
37 ± 0.5°C by keeping the body warm with a thermostatically controlled heated pad and a
flow of warm air. The animals were kept warm by an electric heating pad during the
transportation to and from the irradiator.
After the last tumor volume measurements on day 6, the animals were euthanized, tumors
removed, fixed, and sectioned. Microscopic examination (H & E staining) of the tissue
around the implanted LiPc deposits was performed to confirm its location in the tumor.
Statistical Analysis
A paired t-test was used to determine the statistical significance of the changes in pO2 and
tumor volume within the group and an unpaired t-test was used to determine the significance
between groups. The paired comparison reduces the effects of animal to animal
heterogeneity and eliminates differences of the baseline pO2. The Chi-Square test was used
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to compare the distribution of percentage (%) of tumors with an increase in pO2 of more
than 50% from the baseline during carbogen inhalation when compared with day 1. The tests
were two-sided, and a change with p < 0.05 was considered significant. All data are
expressed as mean ± SEM; N is the number of animals in each group.
RESULTS
Effect of carbogen inhalation on tumor pO2
No significant difference in the baseline and pre-treatment tumor pO2 was observed, in the
CB group, Figure 1 and Table 1. There were also no apparent effects of the tumor growth on
tumor pO2 over days. The increase in the mean tumor pO2 during carbogen inhalation at 1 –
15, 16 – 30, 31 – 45, 46 – 60 min on day 1 - day 5 were significantly higher than the
baseline and pre-treatment pO2 (p <0.05 or p < 0.01), Figure 1. These results indicate that
the carbogen inhalation provided a significant and consistent increase in tumor pO2, with T
max at 22.9 ± 3.6 min to 31.2 ± 4.1 min from day 1 to day 5, Table 1. The tumors were
irradiated during T max to determine the effect of carbogen or 30% O2 inhalation on the
therapeutic efficacy in the CB/RT, 30%O2/RT and CB/Sham RT groups.
The percentage of tumors with an increase in pO2 of more than 50% from the baseline
within 15 min and 30 min of carbogen inhalation on each day are shown in Figure 2. The
results indicate a significant decrease in the response of the tumors to carbogen on day 5 as
compared to day 1.
Tissue pO2 and growth of tumors in mice breathing 30% O2 or carbogen with/without RT
The temporal changes in the tumor pO2 observed in the CB/RT, 30% O2/RT and CB/sham
RT groups are summarized in Figure 3 (a – c). No significant change in the baseline and
pretreatment tumor pO2 was observed in the CB/RT and CB/sham RT groups during 5 days
of experiments (Figure 3 d & f). However, the pre-treatment tumor pO2 of 30% O2/RT
group increased significantly on day 5 as compared to day 1 (Figure 3 e). A significant
increase in the tumor pO2 in CB/RT and CB/sham RT groups was observed at 15 min post
carbogen inhalation on days 1 – 5 and days 1 – 4, respectively, as compared to baseline pO2
(Figure 3 d & f). No such changes in the tumor pO2 were observed in 30% O2/RT group
over days (compared to baseline and pretreatment pO2, Figure 3e).
In the CB/RT and CB/sham RT groups, the percentage (%) of tumors with an increase in
pO2 of more than 50% from the baseline within 15 min of carbogen inhalation significantly
decreased on day 5 as compared with day 1 (Figure 4 a & c), while no such changes were
observed in 30% O2/RT group, (Figure 4b).
No significant difference in the baseline tumor volume was observed between groups, Table
2. However, irradiation resulted in a significant decrease in the tumor growth in CB/RT and
30% O2/RT groups as compared to CB and CB/sham RT groups. Furthermore, a significant
decrease in the tumor growth was observed in the CB/RT as compared to 30% O2/RT group
on days 5 and 6 (Figure 5).
Morphologic examination of the location of LiPc in the tumor
Gross and microscopic examination (H & E staining) of the tissue around the LiPc deposits
confirmed that the deposits were in the interstitial compartment of the tumor tissue with no
evidence of edema or infiltration of inflammatory cells. Although, some accumulation of red
blood cells and necrotic cells around the LiPc deposits was observed in some samples, but
these were not caused by the LiPc implants, rather it reflects the normal histological pattern
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of the tumor. This is consistent with the previous report on the histological appearance of
RIF-1 tumors (29).
DISCUSSION
It is well known that hypoxic cells, as often occur in tumors, are radioresistant and require
nearly three times as much radiation to achieve an equivalent cell kill than oxygenated
cells (30). Mean tumor pO2 of less than 10 mmHg have been shown to correlate with
treatment failure (4, 31–33). Consequently, several approaches to reduce tumor hypoxia have
been developed but only a modest success could be achieved, perhaps due to lack of
appropriate techniques that can be used to follow the changes in tumor pO2 during such
treatments. With the development of EPR oximetry, it is now possible to repeatedly assess
tumor pO2 to optimize the timing of radiotherapy and efficaciously combine it with other
therapeutic modalities. EPR oximetry requires a onetime implantation of the oximetry probe
using 23 – 25 gauge needles in a tissue of interest but rest of the measurement procedure is
entirely non-invasive and provides repeated assessments of localized changes in the tissue
pO2 during treatments (34, 35). Such measurements are not feasible with techniques such as
polarographic electrodes or Oxylite as the measurement procedure is invasive and cannot be
repeated in the same tumors at different time points (or days).
These results are from our ongoing studies to characterize the changes in tumor pO2 induced
by carbogen, with the aim to enhance radiotherapeutic outcomes by scheduling radiation at
times of increases in tumor pO2. The RIF-1 tumors were hypoxic and the baseline/
pretreatment pO2 were stable during 5 days of repeated measurements in CB, CB/RT and
CB/sham groups. A significant increase in the tumor pO2 was observed within 15 min of
carbogen inhalation, with the time to reach the maximum tumor pO2 at around 22 – 32 min.
A similar increase in the tumor pO2 was observed in the CB/sham group, which remained at
an oxygenated level after sham irradiation, Figure 4. These results confirm that in the CB/
RT group, the tumors were irradiated when a significant increase in tumor pO2 occurred
during carbogen breathing.
The dynamic response of tumor pO2 during carbogen inhalation has varied among studies.
Bussink (8) reported a rapid increase in the tumor pO2 using Oxylite, with the mean time to
reach maximum pO2 at approximately 3.9 (0.8–14) min and 3.6 (0.7–16) min in E102 and
E106 glioblastoma xenografts, respectively. Gu et al. reported a significant increase in
subcutaneous mammary adenocarcinoma tumors pO2 within 8 min of carbogen breathing
which gradually increased over the next 12 min (36). Using polarographic electrodes, Thews
et al. observed a slow increase in the pO2 of subcutaneous rat DS-sarcomas over 15 min
during carbogen challenge (37). Using EPR oximetry, we have reported a significant
increase in the intracerebral F98 tumor and contralateral brain pO2 within 15 min of
carbogen inhalation (38). These results indicate that the time to achieve a significant
increase in tumor pO2 with carbogen seems to depend on the tumor type, tumor location,
and possibly tumor size.
Approximately half of the tumors had an increase in pO2 of greater than 50% from the
baseline within 15 min of carbogen inhalation on day 1 to day 4 (Figure 2 and 4) but pO2
significantly declined on day 5 as compared to day 1. This is likely due to a combination of
several factors, such as an increase in interstitial pressure, compromised tumor vasculature
with increase in tumor size and increase in necrotic areas in tumor over days(19).
Carbogen breathing (CB) during irradiation resulted in a significant increase in tumor pO2
and significant suppression of tumor growth compared to the 30%O2/RT, CB and CB/sham
groups on day 3 to day 6. These results are consistent with the previous study employing
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carbogen inhalation with radiotherapy of intracerebral tumors (38). Our results suggest that
the observed changes in the tumor pO2 could be used as a marker to optimize radiotherapy.
The pretreatment tumor pO2 increased significantly on day 5 as compared to day 1 (Figure 3
e) in the 30%O2/RT group. These results are in agreement with Znati et al. who reported an
increase in tumor oxygenation when the total dose of more than 10 Gy were used (39) and
our previous reports in which a significant increase in pre- treatment tumor pO2 was
observed on day 4 and day 5 after fractionated radiation (18, 24).
In conclusion, these results provide unambiguous quantitative information on the
effectiveness of carbogen in enhancing tumor oxygenation over the course of 5 days to a
level that significantly increased tumor response to radiotherapy. Since the time to achieve a
significant increase in tumor pO2 is likely to vary with the tumor type, size, and location,
EPR oximetry could be potentially used to repeatedly monitor tumor pO2 during hypoxia
modifying interventions and enhance efficacy by scheduling radiations at times of increases
in tumor pO2. In vivo EPR oximetry is currently being tested to measure tissue pO2 in the
foot of healthy volunteers with the goal to diagnose and optimize the treatment of peripheral
vascular disease in diabetic patients (20). EPR oximetry is also being tested in patients with
superficial tumors undergoing chemoradiation with the aim to optimize outcome by
scheduling treatments at times of optimal tumor oxygenation (20, 21).
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Figure 1.
Average change in the tumor pO2 during baseline (○: baseline pO2 averaged from 20 min
measurements) and response to 60 min of carbogen inhalation (▲: 1–15 min; ◆: 16–30 min;
■: 31–45 min; ●: 46–60 min). *p<0.05, **p<0.01 compared with baseline and pretreatment
pO2 (paired t-test).
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Figure 2.
The percentage change in tumors with pO2 higher than 50% of the baseline (white column)
and less than 50% of the baseline (black column) within 15 min (a) and 30 min (b) of
carbogen inhalation in CB group on each day. *p<0.05, compared with day 1 (Chi-Square
test).
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Figure 3.
The time course of mean RIF-1 tumor pO2 during baseline and pretreatment pO2 (first 20
min) and during (a) CB/RT, (b) 30%O2/RT and (c) CB/sham RT on day 1 to day 5 (◆: Day
1; ◇: Day 2; ●: day 3; ○: day 4; ■: day 5). The arrows indicate the time when the inhaled
gas was switched from 30% O2 to carbogen. Averaged baseline and pretreatment (d–f, white
column) and the changes in pO2 in CB/RT (d, black column: averaged for 15 min CB),
30%O2/RT (e, grey column: averaged for 15 min 30%O2) and CB/sham RT (f, dense
downward diagonal: averaged for 15 min CB and wide upward diagonal: averaged for 10
min CB after irradiation). *p<0.05; **p<0.01, compared with baseline and pretreatment pO2
on each day (paired t-test), †p<0.05, compared with baseline pO2 on day 1 (unpaired t-test).
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Figure 4.
The percentage change in tumors with pO2 higher than 50% of the baseline (white column)
within 15 min of carbogen inhalation in CB/RT group (a); 30%O2 in 30%O2/RT group (b);
and carbogen inhalation in CB/sham RT group (c), on each day. *p<0.05, compared with
day 1 (Chi-Square test).
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Figure 5.
The change in tumor volume from baseline (day 1) in mice treated with or without RT. ◇:
CB; ●: CB/RT; ■: 30%O2/RT; △: CB/sham RT groups. Data are the mean ±
SEM. ‡p<0.05, ‡‡p<0.01, compared with the CB group, ‡p<0.05, compared with 30%O2/RT
group (two-tailed unpaired t-test).
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Table 1
Baseline/pretreatment pO2, maximum pO2 and time to reach to maximum pO2 in CB group on 5 consecutive
days
Time (days) pO2 base/pre-treatment (mmHg) pO2 max (mmHg) T max (min)
1 7.9±0.9 22.1±3.6 22.9±3.6
2 8.5±1.1 25.7±5.5 27.1±2.4
3 8.9±1.1 17.2±2.2 28.9±4.4
4 9.1±1.1 20.1±3.4 29.5±3.7
5 8.8±1.0 16.6±1.4 31.2±4.1
Abbreviations: pO2 base/pretreatment: baseline pO2/pretreatment pO2; pO2 max: maximum pO2; T max: time to reach maximum pO2.
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Table 2
Absolute baseline/pretreatment tumor volume (mm3, mean ± SEM) in CB/RT, 30%O2/RT and CB/sham RT
groups on 6 consecutive days
Time (days) Groups
CB/RT 30%O2/RT CB/sham RT
1 163.2±16.4 159.6±22.9 163.5±8.6
2 204.2±19.3 201.7±27.2 222.8±19.0
3 247.2±21.2 254.5±30.2 322.4±34.5
4 281.9±23.8 319.2±38.3 414.0±44.5
5 303.3±24.4 372.7±47.2 517.7±41.4
6 323.8±25.9 428.2±49.9 647.2±46.7
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